A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer
研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]The Second Affiliated Hospital of Anhui Medical University[3]Anhui Chest Hospital[4]Huazhong University of Science Tongji Hospital, Tongji Medical College
研究目的：
This is a randomized, double-blind, multicenter phase III clinical study to evaluate efficacy and safety of anlotinib hydrochloride capsule combined with chemotherapy versus placebo combined with chemotherapy as first-line treatment in subjects with advanced non-squamous cell non-small cell lung cancer.
